AUTHORS
Umair Munawar, PhD, Christina Mathilde Verbruggen, PhD2, Seungbin Han3, Ann-Sophie Hainold4, Silvia Nerreter5, Shilpa Kurian6, Cornelia Vogt7, Emma Besant8, Berkant Naldemirci9, Sven Neubert10, Yoko Tamamushi, MD11, Christine Riedhammer12, Johanna Lehmann13, Leo Rasche Jr, MD14, Markus Sauer15, Hermann Einsele, MD, PhD16, Torsten Steinbrunn, MD, PhD17, K. Martin Kortüm, MD18, Johannes Waldschmidt, MD19
AFFILIATIONS
1 University Hospital Wuerzburg, Wuerzburg, Germany
2 University Hospital Wuerzburg, Wuerzburg, Germany
3 University Hospital Wuerzburg, Wuerzburg, Germany
4 University Hospital Wuerzburg, Wuerzburg, Germany
5 University Hospital Wuerzburg, Wuerzburg, Germany
6 University Hospital Wuerzburg, Wuerzburg, Germany
7 University Hospital Wuerzburg, Wuerzburg, Germany
8 University Hospital Wuerzburg, Wuerzburg, Germany
9 University Hospital Wuerzburg, Wuerzburg, Germany
10 University Hospital Wuerzburg, Wuerzburg, Germany
11 University Hospital Wuerzburg, Wuerzburg, Germany
12 University Hospital Wuerzburg, Wuerzburg, Germany
13 University Hospital Wuerzburg, Wuerzburg, Germany
14 University Hospital Wuerzburg, Wuerzburg, Germany
15 University of Wuerzburg, Wuerzburg, Germany
16 University Hospital Wuerzburg, Wuerzburg, Germany
17 University Hospital Wuerzburg, Wuerzburg, Germany
18 University Hospital Wuerzburg, Wuerzburg, Germany
19 University Hospital Wuerzburg, Wuerzburg, Germany
ABSTRACT
Background:
Oncogenic KRAS mutations occur in 20-25% of MM patients and are enriched in relapsed/refractory disease. However, their impact on immune target expression on malignant plasma cells remains poorly understood. As CD38 expression is a key determinant of response to anti-CD38 immunotherapy, we investigated whether oncogenic KRAS remodels the MM surfaceome and whether these changes can be reversed by the novel RAS(ON) inhibitor daraxonrasib.
Methods:
We generated isogenic cell models by introducing the patient-derived activating hotspot mutation KRAS G12A into OPM-2 cells via the Sleeping beauty transposon system. RT-PCR and Direct stochastic optical reconstruction microscopy (dSTORM) were applied for transcript quantification and high-resolution receptor density estimation of the immunotherapeutic targets such as CD38 and BCMA, respectively. Daratumumab-mediated cytotoxicity was evaluated in co-culture with healthy donor PBMCs. Cell viability following daraxonrasib treatment was determined using AlamarBlue and luminescence based assays.
Results:
The KRASG12A model showed a significantly reduced cell surface CD38 expression compared with wildtype (Wt) controls, demonstrating an approx. 30% decrease in receptor density as measured by dSTORM imaging (12.2 ± 1.5 vs 17.9 ± 1.6 localization clusters/µm2, p=0,012). Consistent with CD38 downregulation, KRAS-mutant cells exhibited significantly reduced sensitivity to daratumumab across the tested concentration range compared with KRAS-Wt cells.
Daraxonrasib was subsequently titrated and demonstrated dose-dependent cytotoxic activity in both cell models. Importantly, sublethal doses of daraxonrasib (10-1000nM for 24 hours) induced a significant 2.5- to 3-fold increase in CD38 transcript levels in KRASG12A mutant cells (p<0,05). To determine whether this inhibitor-induced upregulation translates into a functional effect, cells were pretreated with 100 nM of daraxonrasib for 24 h, washed, and subsequently exposed to daratumumab (0,001-10 µg/ml) in the presence of healthy donor PBMCs in 10:1 (Effector to Target) ratio. We observed that daratumumab sensitivity was restored in KRASG12A mutant cells across the tested concentration range (0,01-10 µg/ml, p<0,05). In contrast, daraxonrasib pretreatment did not further enhance daratumumab activity in KRASWt cells indicating that the sensitizing effect is specific to the KRAS-driven resistant phenotype. Additional studies investigating the impact of daraxonrasib treatment on other immune targets, including BCMA and GPRC5D, as well as additional patient-derived KRAS hotspot mutations (Q61 and A146), are ongoing and will be presented.
Conclusion:
Our data demonstrate that oncogenic KRAS suppresses CD38 surface expression and reduces sensitivity to daratumumab in MM cells. Pharmacologic inhibition of RAS signaling with daraxonrasib reverses this phenotype by restoring CD38 expression and re-sensitizing KRAS-mutant MM cells to immunotherapy with Daratumumab. These findings identify KRAS signaling as a regulator of immune target expression in MM and provide a rational for combining RAS inhibition with CD38-directed therapies in patients with RAS-mutant MM.
DISCLOSURES
Umair Munawar, PhD: No relevant conflicts of interest to declare.